Clinical trial CA045-001
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma
Cancers | |
---|---|
Organ | Skin |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | BMS - Bristol Myers Squibb int. |
EudraCT Identifier | 2018-001423-40 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03635983 |
Inclusion criteria | Stage III or IV, unresecable |
Last update |